Fig. 4From: Urine metabolomics for assessing fertility-sparing treatment efficacy in endometrial cancer: a non-invasive approach using ultra-performance liquid chromatography mass spectrometryROC curves for the proposed diagnostic model. ROC curve based on urine biomarker panel in discovery group; B. ROC curve of 10-fold cross-validation of the biomarker panel; C. Predicted probability plot of metabolite panelBack to article page